vs
Natera, Inc.（NTRA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Natera, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的18.7倍（$665.5M vs $35.5M），Natera, Inc.净利率更高（7.1% vs -304.2%，领先311.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 39.8%），Natera, Inc.自由现金流更多（$37.8M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 34.5%）
Natera是总部位于美国得克萨斯州奥斯汀的临床基因检测企业，主打无创游离DNA（cfDNA）检测技术，业务覆盖女性健康、肿瘤及器官健康三大核心赛道。其自研专利技术结合前沿分子生物学手段与生物信息学工具矩阵，可实现单管血液样本中低至单个分子级别的高灵敏度检测。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NTRA vs RXRX — 直观对比
营收规模更大
NTRA
是对方的18.7倍
$35.5M
营收增速更快
RXRX
高出641.9%
39.8%
净利率更高
NTRA
高出311.3%
-304.2%
自由现金流更多
NTRA
多$85.1M
$-47.3M
两年增速更快
RXRX
近两年复合增速
34.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $665.5M | $35.5M |
| 净利润 | $47.3M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -3.4% | -304.8% |
| 净利率 | 7.1% | -304.2% |
| 营收同比 | 39.8% | 681.7% |
| 净利润同比 | 187.9% | 39.6% |
| 每股收益（稀释后） | $0.36 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NTRARXRX
| Q4 25 | $665.5M | $35.5M | ||
| Q3 25 | $592.2M | $5.2M | ||
| Q2 25 | $546.6M | $19.2M | ||
| Q1 25 | $501.8M | $14.7M | ||
| Q4 24 | $476.1M | $4.5M | ||
| Q3 24 | $439.8M | $26.1M | ||
| Q2 24 | $413.4M | $14.4M | ||
| Q1 24 | $367.7M | $13.8M |
净利润NTRARXRX
| Q4 25 | $47.3M | $-108.1M | ||
| Q3 25 | $-87.5M | $-162.3M | ||
| Q2 25 | $-100.9M | $-171.9M | ||
| Q1 25 | $-66.9M | $-202.5M | ||
| Q4 24 | $-53.8M | $-178.9M | ||
| Q3 24 | $-31.6M | $-95.8M | ||
| Q2 24 | $-37.5M | $-97.5M | ||
| Q1 24 | $-67.6M | $-91.4M |
毛利率NTRARXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率NTRARXRX
| Q4 25 | -3.4% | -304.8% | ||
| Q3 25 | -16.5% | -3327.6% | ||
| Q2 25 | -20.2% | -916.8% | ||
| Q1 25 | -15.8% | -1297.9% | ||
| Q4 24 | -13.6% | -4042.4% | ||
| Q3 24 | -8.9% | -377.1% | ||
| Q2 24 | -10.6% | -697.4% | ||
| Q1 24 | -20.2% | -698.4% |
净利率NTRARXRX
| Q4 25 | 7.1% | -304.2% | ||
| Q3 25 | -14.8% | -3135.3% | ||
| Q2 25 | -18.5% | -894.2% | ||
| Q1 25 | -13.3% | -1373.3% | ||
| Q4 24 | -11.3% | -3935.5% | ||
| Q3 24 | -7.2% | -367.5% | ||
| Q2 24 | -9.1% | -676.6% | ||
| Q1 24 | -18.4% | -662.4% |
每股收益（稀释后）NTRARXRX
| Q4 25 | $0.36 | $-0.17 | ||
| Q3 25 | $-0.64 | $-0.36 | ||
| Q2 25 | $-0.74 | $-0.41 | ||
| Q1 25 | $-0.50 | $-0.50 | ||
| Q4 24 | $-0.41 | $-0.56 | ||
| Q3 24 | $-0.26 | $-0.34 | ||
| Q2 24 | $-0.30 | $-0.40 | ||
| Q1 24 | $-0.56 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $1.7B | $1.1B |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资NTRARXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | $1.0M | $659.8M | ||
| Q2 25 | $16.0M | $525.1M | ||
| Q1 25 | $17.8M | $500.5M | ||
| Q4 24 | $22.7M | $594.4M | ||
| Q3 24 | $29.5M | $427.6M | ||
| Q2 24 | $90.3M | $474.3M | ||
| Q1 24 | $69.1M | $296.3M |
总债务NTRARXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益NTRARXRX
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.2B | $919.1M | ||
| Q1 25 | $1.2B | $933.9M | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $878.5M | $524.6M | ||
| Q2 24 | $836.5M | $584.4M | ||
| Q1 24 | $794.1M | $401.2M |
总资产NTRARXRX
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.6B | $726.5M | ||
| Q2 24 | $1.5B | $775.9M | ||
| Q1 24 | $1.5B | $557.8M |
负债/权益比NTRARXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.9M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $37.8M | $-47.3M |
| 自由现金流率自由现金流/营收 | 5.7% | -133.1% |
| 资本支出强度资本支出/营收 | 5.4% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.56× | — |
| 过去12个月自由现金流最近4个季度 | $109.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流NTRARXRX
| Q4 25 | $73.9M | $-46.1M | ||
| Q3 25 | $59.4M | $-117.4M | ||
| Q2 25 | $37.6M | $-76.4M | ||
| Q1 25 | $44.5M | $-132.0M | ||
| Q4 24 | $52.9M | $-115.4M | ||
| Q3 24 | $51.8M | $-59.2M | ||
| Q2 24 | $4.0M | $-82.2M | ||
| Q1 24 | $27.0M | $-102.3M |
自由现金流NTRARXRX
| Q4 25 | $37.8M | $-47.3M | ||
| Q3 25 | $37.0M | $-117.6M | ||
| Q2 25 | $11.7M | $-79.6M | ||
| Q1 25 | $22.6M | $-133.8M | ||
| Q4 24 | $34.8M | $-116.7M | ||
| Q3 24 | $35.5M | $-63.8M | ||
| Q2 24 | $-7.7M | $-83.4M | ||
| Q1 24 | $6.7M | $-109.0M |
自由现金流率NTRARXRX
| Q4 25 | 5.7% | -133.1% | ||
| Q3 25 | 6.2% | -2272.5% | ||
| Q2 25 | 2.1% | -413.9% | ||
| Q1 25 | 4.5% | -907.4% | ||
| Q4 24 | 7.3% | -2567.7% | ||
| Q3 24 | 8.1% | -244.6% | ||
| Q2 24 | -1.9% | -578.5% | ||
| Q1 24 | 1.8% | -789.9% |
资本支出强度NTRARXRX
| Q4 25 | 5.4% | 3.5% | ||
| Q3 25 | 3.8% | 4.7% | ||
| Q2 25 | 4.7% | 16.4% | ||
| Q1 25 | 4.3% | 12.4% | ||
| Q4 24 | 3.8% | 28.6% | ||
| Q3 24 | 3.7% | 17.5% | ||
| Q2 24 | 2.8% | 8.2% | ||
| Q1 24 | 5.5% | 48.2% |
现金转化率NTRARXRX
| Q4 25 | 1.56× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
